EECO2 is a leading global provider of researched, tested and proven engineered energy efficiency solutions for the pharmaceutical, biotech and other high tech industries. Specialising in HVAC & associated systems.
WE HELP OUR CLIENTS TO:
EECO2 evaluates the issue presented by the client, with an experienced and knowledgeable team, specialised equipment and proven energy efficiency projects and methods. Each client can expect bespoke projects to suit the site-specific problems, helping the client site to reach corporate and annual energy and emissions targets.
General Services:
Specialised HVAC Services:
EECO2 specialises in energy efficiency of HVAC systems. This is because HVAC systems account for between 50 – 80% of site energy used in the pharmaceutical, life-science and high-tech sectors.
Project scope can span from opportunity identification, monitoring, control and initial concept development through to detailed design, installation, commissioning and validation. EECO2’s core solutions:
Existing HVAC system designed to provide Grade A room conditions at high energy cost. Process changes resulted in requiring a Grade C room as background for a BFS filling line.
Energy savings identified (per year)
Energy cost savings identified (per year)
Emissions reduction (per year)
of CO2
Our brief was to reduce energy demand without compromising on quality or compliance.
Energy savings delivered (per year)
Energy cost savings (per year)
Emissions reduction (per year)
of CO2
EECO2 were commissioned to examine, quantify and report on the opportunities for energy and water usage reduction at a UK vaccine manufacturing facility.
Key objectives included identifying and prioritising ‘quick win’ improvements that could be implemented immediately.
Energy savings identified (per year):
23% reduction in site energy usage
Energy cost savings identified (per year):
Water savings identified (per year):
52% reduction in site water consumption
EECO2 were commissioned to deliver an HVAC energy focussed assessment of a pharmaceutical manufacturing site working together with the site energy/engineering team and other stakeholders.
The HVAC energy assessment is a proven process that guides the site team to identify and prioritise significant energy and carbon projects that have been discussed in detail and are viable for implementation. The assessment had a scope of reviewing the HVAC energy consumption associated with both GMP (sterile product manufacturing) and non-GMP facilities. It covers AHU, distribution systems and BMS controls and the related energy usage associated with conditioning and moving the air.Energy savings identified (per year):
(13,621 MWh)
Energy cost savings identified (per year):
20% reduction in site energy costs
Emissions reduction (per year):
of CO2 emissions
Our client had an issue with very high energy demand driven by the original HVAC system design which was also unable to meet product critical relative humidity conditions during summer months.
Energy savings delivered (per year)
Energy cost savings (per year)
Emissions reduction (per year)
of CO2
Our client was experiencing high energy demand driven by high volumes of treated fresh air to a large number of fume cupboards operating 24/7.
Energy savings delivered (per year)
Energy cost savings (per year)
Emissions reduction (per year)
of CO2
EECO2 was tasked to reduce energy demand at the client site, without compromising on compliance or laboratory safety.
The client site had very high energy demands, driven by original HVAC design and layout with high air change rates and fresh air volumes.
Energy savings identified (per year):
Energy cost savings identified (per year):
Emissions reduction (per year):
of carbon emissions
EECO2 specialises in identifying and delivering energy savings in highly regulated environments for global businesses desiring to reduce energy consumption, cost & carbon footprint. EECO2 supported this Top 10 Pharmaceutical Manufacturer in delivering Global Energy Reduction Projects.
Energy savings identified (per year):
Energy cost savings identified (per year):
21% reduction in site energy costs
Emissions reduction (per year):
of CO2 emissions
EECO2 was appointed to perform a HVAC energy audit and deliver a prioritised implementation plan for a large R&D facility located in Philadelphia. This was to allow the client to allocate budgets and resources to meet a phased implementation plan for the next 3 years in order to deliver the benefits identified.
Energy savings identified (per year):
Energy cost savings identified (per year):
22% reduction in site energy costs
Emissions reduction (per year):
of carbon emissions
EECO2 performed an ESOS audit, feasibility study and completed energy saving projects on a client site, which focussed on the buildings HVAC systems.
The Energy Savings Opportunity Scheme (ESOS) is the UK’s response to Article 8 of the European Commission’s Energy Efficiency Directive. It is a mandatory energy assessment scheme for organisations in the UK that meet the qualification criteria. The aim is to cut carbon emissions, by requiring large businesses to identify energy reduction measures and make energy savings. ESOS assessments are audits of the energy used by their buildings, industrial processes and transport to identify cost-effective energy saving measures.
Energy savings identified (per year):
17% reduction in site energy consumption
Energy cost savings identified (per year):
15% reduction in site energy costs
Emissions reduction (per year):
of CO2
You always open our eyes to the savings opportunities that exist and how to go about implementing them. Thanks.
Client Senior Manager
Global top 10 pharmaceutical company
The EECO2 team demonstrated a thorough understanding of laboratory air systems. The data obtained was instrumental in formulating our energy reduction strategy… also their flexibility (weekend working) was appreciated.
Site Facilities Manager
Global pharmaceutical manufacturer, UK
It’s going to be a tough year and to know that we have such a good team supporting some of these changes makes the job a lot easier.
Manufacturing Support Manager
Global pharmaceutical manufacturer, South Africa
The service provided by EECO2 was clearly explained by Keith during the initial phone meeting. Everything which was promised in the contract was delivered within quoted price and timeline. EECO2 has recognised multiple savings opportunity for us.
Procurement Manager
Global pharmaceutical manufacturer
I have worked with EECO2 before, but in the years since they have enhanced and refined their methodology to drive a greater value proposition. Nice job Rob and team, you guys exceeded our expectations!
Engineering Director
Global pharmaceutical manufacturer
Great job guys. Imagine if this is indicative of the savings that could be achieved at every biologics site? That water target suddenly looks easy!
EHS Director
Global pharmaceutical manufacturer
The engineering team at EECO2 are easy to work with and have great experience in the field. Their advice is based in real world experience that is clear to understand and is applicable.
Site Energy Lead
Consumer health company
EECO2 helped us in a very professional way to identify and realize savings in our site HVAC operations.
Head of Engineering Site Support
Global consumer health company
A new two-part article has been published by Clean Air and Containment Review (CACR). The article, by Shuji Chen (EECO2), Andrew Butterworth (EECO2) and L. Jiang (University of Liverpool), appears in CACR issue 37 (Winter/Spring 2019) and is entitled ‘Air quality indices and cleanroom ventilation equations, and their application in a cleanroom HVAC system. Part…
This year EECO2’s Andrew Butterworth will be presenting on the poster entitled ‘Energy Efficiency in Cleanrooms’.The poster explores the history of cleanrooms and goes on to explain the most recent technical advancements in the monitoring and controlling areas of cleanroom management. During Andrew’s presentation, he will introduce the Intelligent Cleanroom Control System (ICCS), which applies intelligent…
AbbVie
Aesica
ALKERMES
Allergan
Amgen
AstraZeneca
BAYER
Catalent
Eli Lilly
GlaxoSmithKline
Novartis
Pfizer
Pharmavite
Purogenix
Sanofi
